Molecular Formula | C9H5BrN2O3 |
Molar Mass | 269.05 |
Density | 2.06±0.1 g/cm3(Predicted) |
Melting Point | 160~170℃ |
Boling Point | 353.8±52.0 °C(Predicted) |
Solubility | DMSO: 13mg/mL |
Appearance | solid |
Color | white |
pKa | -1.18±0.20(Predicted) |
Storage Condition | +2C to +8C |
WGK Germany | 3 |
biological activity | NS-2028 is a highly selective soluble guanylate cyclase (sGC) inhibitor, the IC50 values for the basal and NO-stimulated enzymatic activities were 30 nM and 200 nM, respectively. NS-2028 inhibition of soluble guanylate cyclase activity in mouse cerebellar homogenate and neuronal NO synthase, IC50 values were 17 nM and 20 nM. NS-2028 inhibition of 3-morpholino-sydnonimine (SIN-1) formation of cyclic GMP in cultured human umbilical vein endothelial cells with an IC50 value of 30 nM. NS-2028 is commonly used in the study of Nitric oxide signaling pathway, which completely inhibits the NO-dependent relaxation response (1 μm) in non-vascular smooth muscle. NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability. |
Target | IC50: 30 nM |
Cell Line: | HUVEC cells HUVEC cells |
Concentration: | 10 μM 10 μM |
Incubation Time: | 24 hours 30 mins |
Result: | Decreased cell numbers in culture. Attenuated VEGF-enhanced p38 phosphorylation. Inhibits VEGF-induced angiogenesis in vivo. |
Animal Model: | Rabbit |
Dosage: | 1 g/L |
Administration: | Deliver orally; 1g/L; 8 days |